<p>Feasibility and Utility of Incorporating Patient-Reported Outcomes into Surveillance Strategies for Advanced Lung Cancer</p>

Abstract

To identify and to describe patient-reported outcomes (PROs) in lung cancer patients and to evaluate the feasibility and utility of PROs into surveillance strategies, a review was carried out. Patients and Methods: A systematic search in bibliographic databases evaluating the instruments used in PROs of non-small-Cell lung cancer (NSCLC) patients was done. Results: From August 2014 to August 2019, 33 studies were included in this review and 16,491 patients were evaluated. PROs were divided into 6 different categories: 1) PROs as a guide in therapeutic choice, 2) PROs as indicator of disease progression, 3) agreement between PROs and the evaluated parameters, 4) PROs to evaluate the effects of immunotherapy, 5) need to deepen the knowledge of PROs, and 6) use of new electronic PROs. Conclusion: The most frequently used instruments are EORTC QLQ-30 (16, 50%) and EORTC LC-13 (14, 43.75%) and in some studies (37.5%) they are used together. For different reasons (disease progression, adverse event, death, incomplete participation, etc.), the completion of these instruments decreased over time from baseline to subsequent measurements. This review demonstrates that PROs can play an important role as part of health care, and that routine use implementation could improve patient management in addition to the traditionally collected outcome.

Patient Perspectives on Value Dimensions of Lung Cancer Care: Cross-sectional Web-Based Survey

“…A specific questionnaire was designed to measure the aspects of QoL considered most important by patients and their caregivers. This questionnaire covered all dimensions covered by the most commonly used PRO (patient-reported outcomes) instruments for QoL evaluation of patients with LC [7] (Functional Assessment of Cancer Therapy-Lung scale, EQ-5D, the European Organization for Research and Treatment of Cancer's Core Quality of Life questionnaire, and the European Organization for Research and Treatment of Cancer's Core Quality of Life in lung cancer 13-item questionnaire), as well as the ICHOM standard set of patient-centered outcomes for LC.…”

“…It is universally considered a measure of clinical benefit, ensuring a patient-centered treatment approach. There are a number of HRQOL measurement tools currently used for patients with LC in both clinical trials and daily clinical practice [4][5][6][7][8][9][10].…”

“…PROMs can provide a more complete assessment of the benefits and risks of treatment by helping to monitor the response and identify adverse events to therapy. Moreover, when used in daily practice, PROMs may support patient-health care professional (HCP) communication [7,11,12]. Furthermore, growing evidence supports the idea that QoL measures can provide an independent prognostic factor for patients with LC [6,13,14].…”

“…They highlight the relevance of the patient's perspective as a standard outcome measure and the importance of incorporating PROMs in the evaluation of treatment in both clinical trials and clinical practice [9,15,16]. Nevertheless, despite this accepted importance and increasing use, PROMs are still insufficiently incorporated into clinical trials and clinical practice [7,12,15,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32].…”

Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With EGFR-Mutated NSCLC

“…10 , 12 , 13 Similar impacts have been reported for patients with the exon 20ins mutation within the limited existing evidence: disease-related symptoms of fatigue, pain, and shortness of breath are detrimental to HRQoL and negatively affect daily activities, self-care, social activities, and work. 7 The use of PRO measures in clinical trials and clinical practice is increasing, 14 , 15 , 16 and a variety of PRO measures are available for use in a lung cancer population, 12 which can help reveal more on the experience of these patients.…”